Skip to main content
FDA grants breakthrough status to GlycoMimetics' leukemia drug

Breakthrough therapy status has been granted by the FDA to GlycoMimetics' GMI-1271 as a treatment for adult patients with relapsed/refractory acute myeloid leukemia. The company has an ongoing midstage trial to evaluate the combination treatment of GMI-1271 with chemotherapy in AML patients.

Full Story: